Virulence Attenuating Combination Therapy: A Potential Multi-Target Synergy Approach to Treat Pseudomonas Aeruginosa Infections in Cystic Fibrosis Patients

Journal:	*RSC Medicinal Chemistry*
Manuscript ID	MD-REV-12-2019-000566.R1
Article Type:	Review Article
Date Submitted by the Author:	15-Jan-2020
Complete List of Authors:	Shaw, Elana; Emory University Wuest, William; Emory University

ARTICLE

Virulence Attenuating Combination Therapy: A Potential Multi-Target Synergy Approach to Treat *Pseudomonas aeruginosa* Infections in Cystic Fibrosis Patients

Received 00th January 20xx,
Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

Elana Shaw[a] and William M. Wuest *[a,b]

The World Health Organization considers the discovery of new treatments for P. aeruginosa a top priority. Virulence Attenuating Combination Therapy (VACT) is a pragmatic strategy to improve bacterial clearance, repurpose outmoded antibiotics, improve drug efficacy at lower doses, and reduce the evolution of resistance. In vitro and in vivo studies have shown that adding a quorum sensing inhibitor or an extracellular polymeric substance repressor to classical antibiotics synergistically improves antipseudomonal activity. This review highlights why VACT could specifically benefit cystic fibrosis patients harboring chronic P. aeruginosa infections, outlines the current landscape of synergistic combinations between virulence-targeting small-molecules and anti-pseudomonal drugs, and suggests future directions for VACT research.

Introduction

Cystic Fibrosis and *P. aeruginosa* : A Deadly Combination

Individuals with cystic fibrosis (CF) carry a genetic mutation that causes defects in the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The clinical result is an overproduction of thick, viscous mucus in the organ systems, notably the lungs. [1-10]



Figure 1: Depiction of a CF Lung

Airway mucus promotes chronic respiratory infections by physically shielding bacteria from antibiotics and impeding mucocilliary clearance (MCC) of inhaled pathogens. [8, 11]To make matters worse, CFTR-dependent disruptions to complement-mediated immunity impair the ability of monocytes to phagocytose and kill bacteria. [12, 13] Consequently, bacteria thrive in CF lungs and decimate lung function (**Figure 1**).[14] A CFTR-mediated metabolic defect that results in excessive succinate release particularly favors colonization by succinate-metabolizing *Pseudomonas aeruginosa*.[15] Chronic infection by this opportunistic Gram-negative rod is the leading cause of morbidity and mortality for CF patients. [6, 7, 15-18]

Treating *P. aeruginosa* with antibiotics is exceptionally difficult: [19-24] The bacteria's outer membrane under expresses OprD porins by which antibiotics can enter the cell and over expresses RND (Resistance-Nodulation-Division) efflux pumps which expel antibiotics. In addition, *P. aeruginosa* has an inducible gene that codes for AmpC cephalosporinase, a potent beta-lactamase.[24, 25] The bacteria can also mutate to overproduce a protective, charged, alginate-filled biofilm. [9, 26-30] Bacteria in biofilms are up to 1000 times more resistant to antibiotic treatment than their planktonic counterparts, making this mucoidal phenotype infamously difficult to treat. [31-37] To make matters worse, CF patients require frequent antibiotics, placing near-constant pressure on *P. aeruginosa* to evolve new resistance traits. [38]

On average, CF patients initially contract *P. aeruginosa* at age 2.6. By adolescence, 85% of CF patients are actively harboring the bacteria in their lungs. [5, 14, 31, 33] To treat the infection, CF patients cycle through bactericidal monotherapies (including colistin (COL), meropenem (MER), tobramycin (TOB), ceftazidime (CFT), gentamycin (GEN), and azithromycin (AZM)).[23-25, 39-42] Though these

[a] Department of Chemistry, Emory University, 1515 Dickey Drive, Atlanta, Georgia 30322, United States
[b] Emory Antibiotic Resistance Center, Emory University School of Medicine, 201 Dowman Drive, Atlanta, Georgia 30322, United States

monotherapies may dampen *P. aeruginosa* flare-ups, they often fail to achieve full bacterial clearance due to the pathophysiology of CF (**Figure 1**). Bacteria that persist in mucus or biofilms may select for resistance, repopulate the lung, and evolve mucoidy. Each failed treatment attempt increases the likelihood of eventually colonizing a mucoidal multidrug resistant (MDR) or extensively drug-resistant (XDR) strain.[43-50] As such, this current treatment paradigm promotes heinous chronic infections and the World Health Organization (WHO) has assigned top priority to discovering novel therapies for treating *P. aeruginosa*.[17]

Virulence Attenuating Combination Therapy (VACT)

Modern insights into how bacteria specifically interact with the body to cause disease have shed light on new potential drug targets: virulence factors.[44, 51] Virulence inhibitors specifically interfere with the disease process, thereby preserving the host microbiome and minimizing the risk of selecting for resistance.[44, 52] VACT couples virulence-targeting small-molecules (to disarm pathogens) with a bactericidal antibiotic (to kill pathogens).

CF patients suffering from intractable mucoid *P. aeruginosa* are a strong example of a population that could benefit from VACT. In CF lungs, VACT may improve antibiotic efficacy by attenuating biofilm and reducing *P. aeruginosa* virulence factor production to improve the antipseudomonal activity of antibiotics. Substantial *in vitro* and *in vivo P. aeruginosa* VACT studies support this theory. This review summarizes these synergistic combinations in accordance with their virulence target, including 1) quorum sensing (QS) systems and 2) biofilm extracellular polymeric substance (EPS) as well as advocates for future VACT studies that target the Type 3 Secretion System (T3SS) (**Figure 2**).



Figure 3: The QS systems of *P. aeruginosa* are activated when autoinducers bind to transcriptional regulators upregulating autoinducers, virulence factor production, and biofilm formation.

Discussion

Quorum Sensing

QS describes the process by which bacteria communicate with one another by synthesizing, releasing, and responding to the population-dependent concentration of small molecules known as autoinducers (**Figure 3**).[53-55] *P. aeruginosa* secretes two main classes of autoinducer: acyl-homoserine lactones (HSLs) and 2-heptyl-3-hydroxy-4-quinolone (PQS) (**Figure 3**). [56] When the environmental concentration of autoinducers reaches a threshold, transcriptional regulators alter gene expression to promote survival.[55] *P. aeruginosa's* three QS systems, (*Las, Rhl,* and PQS), work together to



Figure 2: Adding a virulence inhibitor to antibiotic therapy improves *P. aeruginosa* killing

control over 300 genes .[57-60] Many of those genes code for potent virulence factors such as LasB elastase, LasA protease, the T3SS, exotoxin A, and pyocyanin.[60-62]

Quorum signaling also allows individual planktonic bacteria to make group-behavioral decisions, notably the choice to form a biofilm (**Figure 3**).[63] During biofilm formation, bacterial cells aggregate together within a self-produced matrix of EPS.[64-66] Inside of the EPS, *P. aeruginosa* can persist, shielded from the host immune system, environmental stresses, and many antibiotics.[37, 63] Additionally, biofilms facilitate horizontal gene transfer, which can lead to the development of resistance.[67]

Functional QS systems are vital for *P. aeruginosa* pathogenesis.[56, 68] In mouse and rat models, *P. aeruginosa* mutants that lacked QS genes caused less lung pathology, suggesting that cell-cell signaling plays a key role in acute virulence.[69, 70] In addition, sputum cultures from CF patients infected with chronic *P. aeruginosa* were discovered to contain significant amounts of HSLs and PQS, indicating that all three QS systems are deeply involved in human infection.[56, 71, 72] Thus, selectively perturbing *P. aeruginosa's* QS systems with small molecules is an extremely promising strategy for curtailing pathogen virulence in both acute and chronic infections.

Quorum Sensing Inhibitors and VACT

Small molecule quorum sensing inhibitors (QSIs) have demonstrated therapeutic anti-pseudomonal potential.[73-77] Alone, they have been found to reduce virulence factor production, biofilm formation, bacterial motility, and pathogen virulence.[78-81] In mouse and rat infection models, QSIs alone induced immunogenicity, improved bacterial clearance, decreased lung pathology, and improved survival.[69, 70, 78, 82]

The addition of a QSI to antibiotic therapy generally attenuates biofilm to improve antibiotic penetration into the cell while also reducing virulence factor production. Strong QSI candidates for VACT must be non-cytotoxic to human cells and synthetically accessible (<5 steps) or commercially available (for feasible large-scale testing). Laboratories have been exploring VACT *in vitro* and *in vivo* with promising results as discussed herein.

Furiga and colleagues took inspiration from the structure of C_4-HSL (**Figure 3**), a key signaling molecule in CF lung infections, to develop N-(2-pyrimidyl) butanamide (**C11**) (**Table 1, Entry A**). **C11** downregulates *las* and *Rhl* QS systems, decreasing virulence factors LasB and RhlA. **C11** also notably attenuates both aerobic biofilms and the more robust anaerobic biofilms that predominate in CF lung infection. When combined with CIP, TOB, and COL, **C11** inhibited biofilm in a dose-dependent manner to improve antibiotic efficacy. They hypothesize that **C11** tampers with QS, causing the bacteria to transition from a biofilm to a planktonic state where antibiotics have easier access for killing. **C11** is a strong target for *in vivo* studies because it is stable, not cytotoxic to human cells, and synthetically accessible.[84]

Table 1: QSI chemical structures and VACT testing summary

Entry	Structure	Synergy with:	Tested *in vitro*?	Tested *in vivo*?
A		CIP, TOB, COL	Yes	No
B		CIP	Yes	No
C		TOB	Yes	No
D		TOB	Yes	Yes
E		AZM	Yes	Yes
F		TOB	Yes	No
G		CIP	Yes	Yes
H		TOB, MER	Yes	No

Similarly inspired by the structure of HSLs, Bortolotti and colleagues conjugated an antagonistic C_{12}-HSL analog to CIP. They observed that their hybrid molecule, **ET37**, reduced biofilm formation and the development of CIP tolerance in clinical strains of *P. aeruginosa* (**Table 1, Entry B**).[85]

Aware that linolenic acid (LNA), an essential fatty acid, has antimicrobial properties, Chanda *et al.* added LNA to TOB therapy and found that the combination synergistically attenuated biofilm and virulence factor production by interfering with all three QS systems (**Table 1, Entry C**).[89] The LNA and TOB combination is promising for future *in vivo* exploration and eventual studies in CF patients for two reasons: 1) The regiment is less toxic than TOB alone because the addition of LNA allowed TOB efficacy at lower doses and 2) The VACT has been found to disrupt the production of alginate, a key contributor to chronicity in *P. aeruginosa* lung infections.

Work by Brackman and colleagues showed the addition of Baicalin Hydrate (BH) to TOB significantly increased biofilm killing *in vitro* (**Table 1, Entry D**). They also found that a VACT regiment of BH and

TOB improved survival in a *C. elegans* infection model.[90] BH is commercially available, making larger-scale VACT studies (for example, in conditions that mimic the CF lung environment) very feasible.

Berberine (BER) is an isoquinolone alkaloid that has been approved for over-the-counter use in China to treat gastrointestinal infections and is being studied as an anti-diabetic and antimicrobial.[91, 92] Li and coworkers found that sub-MIC regimens of BER and AZM interfered with the *Las* and *Rhl* QS systems to inhibit biofilm and virulence factor production (notably alginate) (**Table 1, Entry E**). The VACT also proved effective against 10 clinical *P. aeruginosa* isolates cultured from the sputum of CF patients. Excitingly, infected mice treated with a regimen of 0.8 mg/kg of AZM combined with 3.2 mg/kg of BER showed markedly increased survival and decreased lung inflammation.[93]

Intrigued by the antibacterial properties of itaconimides, Fong and colleagues synthesized an analog library based on structure-activity relationships (SAR) and found that 10 μM (non-cytotoxic up to 40 μM) of itaconimide **12a** in combination with TOB completely eradicated an entire population of 72 hour old *P. aeruginosa* biofilm (**Table 1, Entry F**). They hypothesize that **12a** works by inhibiting the PQS system via the *Las* system. [94] The VACT's ability to entirely remove preformed biofilms may suggest exciting utility against chronic mucoid infection. However, before initiating further clinically oriented studies, it is necessary to test **12a** for reactivity with thiol containing compounds such as glutathione. Such reactivity has been linked to cell-death.[95]

Using bioisoteric modification of known, single-target inhibitors, Thomann et.al. developed compound **6**, which is a multi-target drug that simultaneously inhibits the transcriptional regulator, *PqsR,* and a key enzyme for PQS production, *PqsD* (**Table 1, Entry G**). [96] Alone, **6** interfered with iron metabolism, decreased virulence factor production, inhibited biofilm formation (IC_{50}= 100 μM) and eDNA production. It also demonstrated *in vivo* efficacy by increasing the survival of *Galleria mellonella* (low toxicity observed). The VACT combination of 1 μM CIP + 50 μM **6** restored CIP activity against *P. aeruginosa* biofilm. They hypothesize that this synergy is due to the ability of **6** to inhibit eDNA, which hinders CIP.

Excitingly, Maura and colleagues found that another *PqsR* inhibitor, **M64**, is one hundred times more potent at inhibiting biofilm than compound **6** (**Table 1, Entry H**).[97] Pre-treatment with **M64** restored TOB and MER efficacy against antibiotic-tolerant biofilms. Concurrent treatment with **M64** and MER or TOB decreased biofilm CFU by 178 and 17 times respectively.

In recent years, a plethora of auspicious QSIs have been discovered. Many of these inhibitors are commercially available, have low toxicity, or inhibit alginate (the main component of mucoid *P. aeruginosa* biofilm). For these reasons, such compounds and their synthetic analogs merit VACT studies in the context of CF. A summary of auspicious QSIs for VACT studies can be found in **Table 2**.[78, 79, 81, 98-101]

Extracellular Polymeric Substance Repressors

During the early stages of biofilm formation, bacteria generate a matrix made up of extracellular polymeric substances (EPSs).[102] *P. aeruginosa* produces three EPSs: *Pel, Psl*, and alginate. *Pel* is believed to function as an eDNA cross-linker and has been implicated in the development of antimicrobial resistance.[103] [104] *Psl* may act as a signal to initiate biofilm formation and is a critical structural element of biofilms during the microcolony formation stage.[105] [106]

Pel and *Psl* are exciting targets for VACT because inhibiting EPSs reduces or eliminates biofilm, making bacteria more susceptible to antimicrobials.[104] The Lewenza Lab used a high-throughput gene expression screen to find compounds that repress *Pel*.[107] When studied in combination with COL, polymyxin B (PB), TOB, GEN, and CIP, EPS inhibitors **I7-I11** attenuated mucoidal biofilms to improve antibiotic penetration and efficacy (**Figure 4**). Notably, compound **I7** also demonstrated ability to attenuate biofilm in mucoidal *P. aeruginosa*, making it a prime candidate for *in vivo* exploration in the context of CF.

Table 2: Summary and evaluation of promising QSIs not tested for synergy

Compound	Reduces virulence factors:	Inhibits biofilm?	Commercially available?
 Pyridoxal Lactohydrazone	alginate, pyocyanin	Yes	No (2 synthetic steps)
 5-Hydroxymethylfurfural	alginate, rhamnolipid (Sub-MIC)	Yes	Yes
 Spiraeoside	elastase, pyocyanin, violacetin	Yes	Yes
 3,5,7-Trihydroxyflavone	pyocyanin	Yes (IC_{85} = 100 µM)	Yes
 Amorfrutin B	elastase, pyocyanin (IC_{50} = 10 µM)	Yes (IC_{50} = 50 µM)	No
 Tyrosol	elastase, pyocyanin	Yes	Yes



Figure 4: Chemical structures of EPS inhibitors by the Lewenza Lab used in VACT

Type 3 Secretion System Inhibitors and VACT

Type 3 Secretion Systems (T3SSs) play leading roles in *P. aeruginosa* virulence and are a strong yet unexplored candidate for VACT.[108, 109] The T3SS is highly conserved amongst gram-negative pathogens and broadly responsible for transferring proteins out of the bacterial cell.[109, 110] *P. aeruginosa* expresses two distinct Type 3 Secretion Systems (T3SSs): The fT3SS and the iT3SS.[111] The fT3SS expels flagellar proteins, enabling chemotaxis and biofilm formation and secreting effector toxins.[111-113] The iT3SS, or injectosome, ejaculates cytotoxic effector toxins (ETA, ExoS, ExoT, ExoU, ExoY) directly into the host cell's cytoplasm (**Figure 5**).[80, 114, 115]

The most potent effector toxin is ExoU. [18, 22] ExoU has been found to lyse lung cells and destroy the alveolar epithelia, leading to septic shock and severe acute lung damage.[116, 117] ExoS inhibits human neutrophils from producing reactive oxygen species (ROS), which are vital for killing phagocytosed bacteria.[118] ExoT inhibits mammalian cytokinesis, causing slowed wound healing. [9, 119] ExoY causes apoptosis.[117, 120] In addition to their individual functions, the four major effector toxins collude to kill and impair alveolar neutrophils and macrophages, severely handicapping the phagocytotic immune response to bacteria.[121]

Inhibiting the T3SS with small-molecules is a highly appealing anti virulence strategy: The T3SS is specific to pathogenic bacteria, limiting the chance of off-target effects.[18, 80, 122-125] In addition, because the T3SS is not vital for the bacteria's survival, disrupting it should not place evolutionary pressure on *P. aeruginosa* to evolve new resistance mechanisms.[126] Ideally, a selective T3SS inhibitor would stop *P. aeruginosa* from impairing phagocytosis, allowing the host immune system to do the killing.[122] However, T3SS inhibitors have never been studied for synergy with bactericidal antibiotics. Several promising T3SS inhibitors and VACT candidates are featured in **Figure 6** and discussed herein. However, for a thorough review of targeting the T3SS to fight *P. aeruginosa*, see Anantharajah *et al*. [127] and Duncan *et al*. [128]



Figure 5: The T3SS secretes effector toxins into the host cytoplasm

Promising T3SS Inhibitors for Future VACT Studies

Sheremet and colleagues studied the activity of Flourothiazinon (FT), a 2,4-disubstituted-4H-[1,3,4]-thiadiazine-5-one, against *P. aeruginosa* infections in a mouse model.[126, 129] They found that mice dosed with 50 mg/kg of FT twice daily for 4 days after being infected with various lethal doses of multi-drug resistant clinical isolates of *P. aeruginosa* often survived the infection and displayed less lung pathology, lower levels of systemic inflammation, increased clearance of bacteria in their lungs and spleen, and no bacteremia. This suggests that at both a systemic level and in the lungs, FT intercepts *P. aeruginosa*'s characteristic attempt to suppress host immunity, improving phagocytotic clearance of pathogen from the cells to allow survival. *In vitro* experiments showed that FT specifically inhibited secretion of ExoT and ExoY and significantly decreased cytotoxicity. They also found that FT restored the ability HeLa cells to phagocytose bacteria in a dose dependent manner. When plated with FT, *P. aeruginosa* growth was not affected. The efficacy, specificity, and documented low toxicity[108] of FT make it a highly promising candidate for VACT.

Anantharajah and colleagues explored two classes of T3SS inhibitors for antibiotic potential: Salicylidine acylhydrides and hydroxyquinolones.[111] These molecular classes were promising as they had previously been found to inhibit transcription of the iT3SS in other gram negative pathogens including *Y. pseudotuberculosis*, *Shigella*, *Salmonella*, and *Chlamydia*.[123-125] The team compared the anti-pseudomonal activity of the two chemical classes by selecting a non-cytotoxic model molecule from each and testing it in a series of *in vitro* experiments. From the salicylidine acylhydrides, they selected INP0341 (SA INP0341), and from the hydroxyquinolines, they selected INP1750 (HINP1750). They found that both INPs reduced *P. aeruginosa's* cytotoxicity in phagocytotic and epithelial eukaryotic cells. Further experimentation revealed that SA INP0341 interferes with iT3SS gene transcription while HINP1750 mediates cytotoxicity by inhibiting a key ATPase homologous to the iT3SS and the fT3SS to decrease ExoS secretion and flagellar motility. HINP1750 had a more robust effect on T3SS inhibition as it was active against both T3SS systems, making it a stronger candidate for future study in acute animal infection models and VACT. However, before such



Figure 6: Promising T3SS inhibitors for future VACT study

studies take place, it is necessary to test the mutagenicity of HINP1750 with an Ames test or its equivalent -- nitroaromatic groups have been linked to mutagenicity and HINP1750 has 2 nitro groups attached to an aromatic ring.[130]

The iT3SS injectosome needle is composed of repeated subunits of a single protein termed PscF. Before PscF is secreted to form the needle, it is protected by two chaperonins, PscE, and PscG. Without protection from the chaperonins, PscF will degrade in the cytosol, and the injectosome needle will not form. Thus, inhibiting the interactions between PscF and the chaperonins will prevent biogenesis of the iT3SS and its resulting cytotoxicity.[80, 115] This effect is confirmed by PscE/PscG knockout studies.[115] In July 2019, Feng and colleagues made a serendipitous discovery that non-bactericidal tanshinones compete with PscF for PscE-PscG binding.[80] They found that dihydrotanshinone 1 (dHTSN1) demonstrated an IC_{50} of 0.68 μM, and dihydrotanshinone (dHTSN) demonstrated an IC_{50} of 1.5 μM in a fluorescence polarization (FP) assay. In addition, the compounds were found by Western Blot to decrease ExoS secretion at concentrations of 100 μM in Ca^{2+} depleted (T3SS stimulating) conditions. Western blot also revealed that the tanshinones repressed *P. aeruginosa*-induced macrophage lysis by reducing bacterial caspase-1 release. Caspase-1 is normally released by the T3SS, further suggesting that the tanshinones inhibit T3SS biogenesis.[131] In mouse models, 90% of mice challenged with LD_{70} of PA01 survived when dosed with either dHTSN or dHTSN1. These mice showed less bacteria in their lungs, lower levels of inflammation, and less alveolar damage. The impressive anti virulence properties of tanshinones demonstrated *in vitro* and *in vivo* make them prime candidates for VACT exploration.

Conclusions

Despite a cornucopia of promising academic work in the development of virulence inhibitors such as QSIs or EPS repressors, these compounds have yet to progress to clinical trials. One potential explanation for this disconnect is that large pharmaceutical companies are likely deterred by the financial risk of such an endeavor for two reasons. 1) The path by which such a compound would pass Phase 3 is unclear and has yet to be evaluated and 2) testing molecules that specifically inhibit virulence and not bacterial growth in humans might raise some ethical questions. However, with antibiotic resistance on the rise, failing to pursue non-bactericidal options, even in combination with approved drugs, is potentially both dangerous and a missed opportunity to revolutionize our antiquated approach to treating infectious disease.

Virulence inhibitors (notably QSIs and EPS repressors) have demonstrated a strong ability to potentiate antipseudomonal antibiotics in both *in vitro* and animal models. There is a long road from *in vitro* and murine model experimentation to clinical testing. However, the early promising results of VACT merit further exploration: First, synergy testing of known and novel QSIs and EPS inhibitors is needed to identify new and potent VACT combinations. Computational screening methods can be used to identify highly specific, multi-target virulence inhibitors for such testing. Second, labs must begin testing VACT regimens in conditions that replicate the CF lung. For example, in the presence of alginate, CF sputum,[132] or in genetically engineered mouse models (GEMM) with CFTR defects. Third, VACT studies with T3SS (and other virulence) inhibitors demand exploration. It is our hope that the next generation of chemists will use virulence-inhibiting small-molecules to resuscitate antibiotics and annihilate resistant bacteria.

Conflicts of Interest

There are no conflicts to declare.

Acknowledgements

The laboratory is supported by the National Institute of General Medical Sciences (GM119426) and the National Science Foundation (CHE1755698). We thank Alexander T. Kim, Amy Solinski, Amber Scharnow, Anna Kaplan, and Ingrid Wilt for valuable suggestions and feedback.

Notes and references

1. Grossman, S.; Grossman, L. C., Pathophysiology of Cystic Fibrosis: Implications for Critical Care Nurses. *Critical Care Nurse* **2005,** *25* (4), 46-51.
2. Haack, A.; Aragão, G. G.; Novaes, M. R. C. G., Pathophysiology of cystic fibrosis and drugs used in associated digestive tract diseases. *World J Gastroenterol* **2013,** *19* (46), 8552-8561.
3. Sheppard, D. N.; Welsh, M. J., Structure and function of the CFTR chloride channel. *Physiol Rev* **1999,** *79* (1 Suppl), S23-45.
4. Schram, C. A., Atypical cystic fibrosis: identification in the primary care setting. *Can Fam Physician* **2012,** *58* (12), 1341-e704.
5. Davies, J. C., Pseudomonas aeruginosa in cystic fibrosis: pathogenesis and persistence. *Paediatr Respir Rev* **2002,** *3* (2), 128-34.
6. Emerson, J.; Rosenfeld, M.; McNamara, S.; Ramsey, B.; Gibson, R. L., Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. *Pediatr Pulmonol* **2002,** *34* (2), 91-100.
7. Shapiro, J. A.; Kaplan, A. R.; Wuest, W. M., From General to Specific: Can Pseudomonas Primary Metabolism Be Exploited for Narrow-Spectrum Antibiotics? *ChemBioChem* **2019,** *20* (1), 34-39.
8. Bhagirath, A. Y.; Li, Y.; Somayajula, D.; Dadashi, M.; Badr, S.; Duan, K., Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. *BMC Pulm Med* **2016,** *16* (1), 174.
9. Hoffman, L. R.; Kulasekara, H. D.; Emerson, J.; Houston, L. S.; Burns, J. L.; Ramsey, B. W.; Miller, S. I., Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression. *Journal of Cystic Fibrosis* **2009,** *8* (1), 66-70.
10. Hartl, D.; Gaggar, A.; Bruscia, E.; Hector, A.; Marcos, V.; Jung, A.; Greene, C.; McElvaney, G.; Mall, M.; Döring, G., Innate immunity in cystic fibrosis lung disease. *Journal of Cystic Fibrosis* **2012,** *11* (5), 363-382.
11. Livraghi, A.; Randell, S. H., Cystic Fibrosis and Other Respiratory Diseases of Impaired Mucus Clearance. *Toxicologic Pathology* **2007,** *35* (1), 116-129.

12. Lovewell, R. R.; Patankar, Y. R.; Berwin, B., Mechanisms of phagocytosis and host clearance of Pseudomonas aeruginosa. *Am J Physiol Lung Cell Mol Physiol* **2014,** *306* (7), L591-L603.
13. Van de Weert-van Leeuwen, P. B.; Van Meegen, M. A.; Speirs, J. J.; Pals, D. J.; Rooijakkers, S. H.; Van der Ent, C. K.; Terheggen-Lagro, S. W.; Arets, H. G.; Beekman, J. M., Optimal complement-mediated phagocytosis of Pseudomonas aeruginosa by monocytes is cystic fibrosis transmembrane conductance regulator-dependent. *Am J Respir Cell Mol Biol* **2013,** *49* (3), 463-70.
14. Lyczak, J. B.; Cannon, C. L.; Pier, G. B., Lung infections associated with cystic fibrosis. *Clin Microbiol Rev* **2002,** *15* (2), 194-222.
15. Riquelme, S. A.; Lozano, C.; Moustafa, A. M.; Liimatta, K.; Tomlinson, K. L.; Britto, C.; Khanal, S.; Gill, S. K.; Narechania, A.; Azcona-Gutiérrez, J. M.; DiMango, E.; Saénz, Y.; Planet, P.; Prince, A., CFTR-PTEN–dependent mitochondrial metabolic dysfunction promotes Pseudomonas aeruginosa airway infection. *Science Translational Medicine* **2019,** *11* (499), eaav4634.
16. Pseudomonas. https://www.cff.org/Life-With-CF/Daily-Life/Germs-and-Staying-Healthy/What-Are-Germs/Pseudomonas/.
17. Govindaraj Vaithinathan, A.; Vanitha, A., WHO global priority pathogens list on antibiotic resistance: an urgent need for action to integrate One Health data. *Perspect Public Health* **2018,** *138* (2), 87-88.
18. Galle, M.; Carpentier, I.; Beyaert, R., Structure and function of the Type III secretion system of Pseudomonas aeruginosa. *Current protein & peptide science* **2012,** *13* (8), 831-842.
19. Qiu, X.; Kulasekara, B. R.; Lory, S., Role of Horizontal Gene Transfer in the Evolution of Pseudomonas aeruginosa Virulence. *Genome dynamics* **2009,** *6*, 126-39.
20. Labaer, J.; Qiu, Q.; Anumanthan, A.; Mar, W.; Zuo, D.; Murthy, T. V.; Taycher, H.; Halleck, A.; Hainsworth, E.; Lory, S.; Brizuela, L., The Pseudomonas aeruginosa PA01 gene collection. *Genome Res* **2004,** *14* (10b), 2190-200.
21. Saderi, H.; Owlia, P., Detection of Multidrug Resistant (MDR) and Extremely Drug Resistant (XDR) P. Aeruginosa Isolated from Patients in Tehran, Iran. *Iranian journal of pathology* **2015,** *10* (4), 265-71.
22. Ader, F.; Le Berre, R.; Faure, K.; Gosset, P.; Epaulard, O.; Toussaint, B.; Polack, B.; Nowak, E.; Viget, N. B.; Kipnis, E.; Guery, B. P., Alveolar response to Pseudomonas aeruginosa: role of the type III secretion system. *Infect Immun* **2005,** *73* (7), 4263-71.
23. Todar, K., Todar's Online Textbook of Bacteriology. In *Pseudomonas aeruginosa* [Online] 2012. (accessed 6/10/19).
24. Lister, P. D.; Wolter, D. J.; Hanson, N. D., Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. *Clin Microbiol Rev* **2009,** *22* (4), 582-610.
25. Smith, W. D.; Bardin, E.; Cameron, L.; Edmondson, C. L.; Farrant, K. V.; Martin, I.; Murphy, R. A.; Soren, O.; Turnbull, A. R.; Wierre-Gore, N.; Alton, E. W.; Bundy, J. G.; Bush, A.; Connett, G. J.; Faust, S. N.; Filloux, A.; Freemont, P. S.; Jones, A. L.; Takats, Z.; Webb, J. S.; Williams, H. D.; Davies, J. C., Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis. *FEMS Microbiol Lett* **2017,** *364* (14).
26. Boyd, A.; Chakrabarty, A. M., Pseudomonas aeruginosa biofilms: role of the alginate exopolysaccharide. *J Ind Microbiol* **1995,** *15* (3), 162-8.
27. Li, Z.; Kosorok, M. R.; Farrell, P. M.; Laxova, A.; West, S. E.; Green, C. G.; Collins, J.; Rock, M. J.; Splaingard, M. L., Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. *JAMA* **2005,** *293* (5), 581-8.
28. Ryall, B.; Carrara, M.; Zlosnik, J. E. A.; Behrends, V.; Lee, X.; Wong, Z.; Lougheed, K. E.; Williams, H. D., The Mucoid Switch in Pseudomonas aeruginosa Represses Quorum Sensing Systems and Leads to Complex Changes to Stationary Phase Virulence Factor Regulation. *PLOS ONE* **2014,** *9* (5), e96166.
29. Martin, D. W.; Schurr, M. J.; Mudd, M. H.; Govan, J. R.; Holloway, B. W.; Deretic, V., Mechanism of conversion to mucoidy in Pseudomonas aeruginosa infecting cystic fibrosis patients. *Proceedings of the National Academy of Sciences* **1993,** *90* (18), 8377-8381.
30. Govan, J. R.; Deretic, V., Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. *Microbiol Rev* **1996,** *60* (3), 539-574.
31. Bjarnsholt, T.; Jensen, P. Ø.; Fiandaca, M. J.; Pedersen, J.; Hansen, C. R.; Andersen, C. B.; Pressler, T.; Givskov, M.; Høiby, N., Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. *Pediatric Pulmonology* **2009,** *44* (6), 547-558.
32. Høiby, N., Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. *BMC Med* **2011,** *9*, 32-32.
33. Heltshe, S. L.; Khan, U.; Beckett, V.; Baines, A.; Emerson, J.; Sanders, D. B.; Gibson, R. L.; Morgan, W.; Rosenfeld, M., Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis. *Journal of Cystic Fibrosis* **2018,** *17* (3), 341-347.
34. Pritt, B.; O'Brien, L.; Winn, W., Mucoid Pseudomonas in cystic fibrosis. *Am J Clin Pathol* **2007,** *128* (1), 32-4.
35. Pressler, T.; Frederiksen, B.; Skov, M.; Garred, P.; Koch, C.; Høiby, N., Early rise of anti-Pseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection—A case control study. *Journal of Cystic Fibrosis* **2006,** *5* (1), 9-15.
36. Potera, C., ANTIBIOTIC RESISTANCE: Biofilm Dispersing Agent Rejuvenates Older Antibiotics. *Environmental Health Perspectives* **2010,** *118* (7), A288-A288.
37. Bjarnsholt, T., The role of bacterial biofilms in chronic infections. *APMIS Suppl* **2013,** (136), 1-51.
38. Lucca, F.; Guarnieri, M.; Ros, M.; Muffato, G.; Rigoli, R.; Da Dalt, L., Antibiotic resistance evolution of Pseudomonas aeruginosa in cystic fibrosis patients (2010-2013). *The Clinical Respiratory Journal* **2018,** *12* (7), 2189-2196.
39. Manno, G.; Cruciani, M.; Romano, L.; Scapolan, S.; Mentasti, M.; Lorini, R.; Minicucci, L., Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre. *International Journal of Antimicrobial Agents* **2005,** *25* (3), 193-197.
40. Pang, Z.; Raudonis, R.; Glick, B. R.; Lin, T.-J.; Cheng, Z., Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. *Biotechnology Advances* **2019,** *37* (1), 177-192.
41. Yayan, J.; Ghebremedhin, B.; Rasche, K., Antibiotic Resistance of Pseudomonas aeruginosa in Pneumonia at a Single University Hospital Center in Germany over a 10-Year Period. *PLOS ONE* **2015,** *10* (10), e0139836.
42. Hancock, R. E. W.; Speert, D. P., Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. *Drug Resistance Updates* **2000,** *3* (4), 247-255.
43. Kohanski, M. A.; Dwyer, D. J.; Collins, J. J., How antibiotics kill bacteria: from targets to networks. *Nat Rev Microbiol* **2010,** *8* (6), 423-435.
44. Clatworthy, A. E.; Pierson, E.; Hung, D. T., Targeting virulence: a new paradigm for antimicrobial therapy. *Nat Chem Biol* **2007,** *3* (9), 541-8.

45. Ventola, C. L., The antibiotic resistance crisis: part 1: causes and threats. *P & T : a peer-reviewed journal for formulary management* **2015,** *40* (4), 277-283.
46. Tan, S. Y.; Tatsumura, Y., Alexander Fleming (1881-1955): Discoverer of penicillin. *Singapore medical journal* **2015,** *56* (7), 366-367.
47. Coates, A. R. M.; Halls, G.; Hu, Y., Novel classes of antibiotics or more of the same? *British journal of pharmacology* **2011,** *163* (1), 184-194.
48. Koch, C., Early infection and progression of cystic fibrosis lung disease. *Pediatr Pulmonol* **2002,** *34* (3), 232-6.
49. Fauvart, M.; De Groote, V. N.; Michiels, J., Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies. *J Med Microbiol* **2011,** *60* (Pt 6), 699-709.
50. Ferroni, A.; Guillemot, D.; Moumile, K.; Bernede, C.; Le Bourgeois, M.; Waernessyckle, S.; Descamps, P.; Sermet-Gaudelus, I.; Lenoir, G.; Berche, P.; Taddei, F., Effect of mutator P. aeruginosa on antibiotic resistance acquisition and respiratory function in cystic fibrosis. *Pediatr Pulmonol* **2009,** *44* (8), 820-5.
51. Brown, S. P.; Cornforth, D. M.; Mideo, N., Evolution of virulence in opportunistic pathogens: generalism, plasticity, and control. *Trends in microbiology* **2012,** *20* (7), 336-342.
52. Cui, J.; Ren, B.; Tong, Y.; Dai, H.; Zhang, L., Synergistic combinations of antifungals and anti-virulence agents to fight against Candida albicans. *Virulence* **2015,** *6* (4), 362-371.
53. Waters, C. M.; Bassler, B. L., QUORUM SENSING: Cell-to-Cell Communication in Bacteria. *Annual Review of Cell and Developmental Biology* **2005,** *21* (1), 319-346.
54. Papenfort, K.; Bassler, B. L., Quorum sensing signal–response systems in Gram-negative bacteria. *Nature Reviews Microbiology* **2016,** *14*, 576.
55. Zhou, Z.; Ma, S., Recent Advances in the Discovery of PqsD Inhibitors as Antimicrobial Agents. *ChemMedChem* **2017,** *12* (6), 420-425.
56. Smith, R. S.; Iglewski, B. H., Pseudomonas aeruginosa quorum sensing as a potential antimicrobial target. *The Journal of Clinical Investigation* **2003,** *112* (10), 1460-1465.
57. Hentzer, M.; Wu, H.; Andersen, J. B.; Riedel, K.; Rasmussen, T. B.; Bagge, N.; Kumar, N.; Schembri, M. A.; Song, Z.; Kristoffersen, P.; Manefield, M.; Costerton, J. W.; Molin, S.; Eberl, L.; Steinberg, P.; Kjelleberg, S.; Høiby, N.; Givskov, M., Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. *EMBO J* **2003,** *22* (15), 3803-3815.
58. Wang, M.; Schaefer, A. L.; Dandekar, A. A.; Greenberg, E. P., Quorum sensing and policing of Pseudomonas aeruginosa social cheaters. *Proceedings of the National Academy of Sciences* **2015,** *112* (7), 2187-2191.
59. Kostylev, M.; Kim, D. Y.; Smalley, N. E.; Salukhe, I.; Greenberg, E. P.; Dandekar, A. A., Evolution of the Pseudomonas aeruginosa quorum-sensing hierarchy. *Proceedings of the National Academy of Sciences* **2019,** *116* (14), 7027-7032.
60. Duan, K.; Surette, M. G., Environmental regulation of Pseudomonas aeruginosa PAO1 Las and Rhl quorum-sensing systems. *Journal of bacteriology* **2007,** *189* (13), 4827-4836.
61. Whiteley, M.; Lee, K. M.; Greenberg, E. P., Identification of genes controlled by quorum sensing in Pseudomonas aeruginosa. *Proc Natl Acad Sci U S A* **1999,** *96* (24), 13904-9.
62. Nadal Jimenez, P.; Koch, G.; Thompson, J. A.; Xavier, K. B.; Cool, R. H.; Quax, W. J., The Multiple Signaling Systems Regulating Virulence in Pseudomonas aeruginosa. *Microbiology and Molecular Biology Reviews* **2012,** *76* (1), 46-65.
63. Solano, C.; Echeverz, M.; Lasa, I., Biofilm dispersion and quorum sensing. *Current Opinion in Microbiology* **2014,** *18*, 96-104.
64. Ghanbarzadeh Corehtash, Z.; Khorshidi, A.; Firoozeh, F.; Akbari, H.; Mahmoudi Aznaveh, A., Biofilm Formation and Virulence Factors Among Pseudomonas aeruginosa Isolated From Burn Patients. *Jundishapur J Microbiol* **2015,** *8* (10), e22345-e22345.
65. Owlia, P.; Nosrati, R.; Alaghehbandan, R.; Lari, A. R., Antimicrobial susceptibility differences among mucoid and non-mucoid Pseudomonas aeruginosa isolates. *GMS Hyg Infect Control* **2014,** *9* (2), Doc13-Doc13.
66. Lam, J.; Chan, R.; Lam, K.; Costerton, J. W., Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. *Infect Immun* **1980,** *28* (2), 546-56.
67. Flemming, H.-C.; Neu, T. R.; Wozniak, D. J., The EPS matrix: the "house of biofilm cells". *J Bacteriol* **2007,** *189* (22), 7945-7947.
68. Bassler, B. L., Small Talk: Cell-to-Cell Communication in Bacteria. *Cell* **2002,** *109* (4), 421-424.
69. Pearson, J. P.; Feldman, M.; Iglewski, B. H.; Prince, A., Pseudomonas aeruginosa Cell-to-Cell Signaling Is Required for Virulence in a Model of Acute Pulmonary Infection. *Infection and Immunity* **2000,** *68* (7), 4331-4334.
70. Wu, H.; Song, Z.; Givskov, M.; Doring, G.; Worlitzsch, D.; Mathee, K.; Rygaard, J.; Hoiby, N., Pseudomonas aeruginosa mutations in lasI and rhlI quorum sensing systems result in milder chronic lung infection. *Microbiology* **2001,** *147* (Pt 5), 1105-13.
71. Erickson, D. L.; Endersby, R.; Kirkham, A.; Stuber, K.; Vollman, D. D.; Rabin, H. R.; Mitchell, I.; Storey, D. G., Pseudomonas aeruginosa Quorum-Sensing Systems May Control Virulence Factor Expression in the Lungs of Patients with Cystic Fibrosis. *Infection and Immunity* **2002,** *70* (4), 1783-1790.
72. Collier, D. N.; Anderson, L.; McKnight, S. L.; Noah, T. L.; Knowles, M.; Boucher, R.; Schwab, U.; Gilligan, P.; Pesci, E. C., A bacterial cell to cell signal in the lungs of cystic fibrosis patients. *FEMS Microbiology Letters* **2002,** *215* (1), 41-46.
73. Gökalsın, B.; Berber, D.; Sesal, N. C., Chapter 9 - Pseudomonas aeruginosa Quorum Sensing and Biofilm Inhibition. In *Quorum Sensing*, Tommonaro, G., Ed. Academic Press: 2019; pp 227-256.
74. Pérez-Pérez, M.; Jorge, P.; Pérez Rodríguez, G.; Pereira, M. O.; Lourenço, A., Quorum sensing inhibition in Pseudomonas aeruginosa biofilms: new insights through network mining. *Biofouling* **2017,** *33* (2), 128-142.
75. Müh, U.; Hare, B. J.; Duerkop, B. A.; Schuster, M.; Hanzelka, B. L.; Heim, R.; Olson, E. R.; Greenberg, E. P., A structurally unrelated mimic of a Pseudomonas aeruginosa acyl-homoserine lactone quorum-sensing signal. *Proceedings of the National Academy of Sciences* **2006,** *103* (45), 16948-16952.
76. Zou, Y.; Nair, S. K., Molecular Basis for the Recognition of Structurally Distinct Autoinducer Mimics by the Pseudomonas aeruginosa LasR Quorum-Sensing Signaling Receptor. *Chemistry & Biology* **2009,** *16* (9), 961-970.
77. Ó Muimhneacháin, E.; Reen, F. J.; O'Gara, F.; McGlacken, G. P., Analogues of Pseudomonas aeruginosa signalling molecules to tackle infections. *Organic & Biomolecular Chemistry* **2018,** *16* (2), 169-179.
78. Kim, B.; ParK, J.-S.; Choi, H.-Y.; Kwak, J.-H.; Kim, W.-G., Differential effects of alkyl gallates on quorum sensing in Pseudomonas aeruginosa. *Sci Rep* **2019,** *9* (1), 7741.
79. Chang, A.; Sun, S.; Li, L.; Dai, X.; Li, H.; He, Q.; Zhu, H., Tyrosol from marine Fungi, a novel Quorum sensing inhibitor against Chromobacterium violaceum and Pseudomonas aeruginosa. *Bioorganic Chemistry* **2019,** *91*, 103140.
80. Feng, C.; Huang, Y.; He, W.; Cheng, X.; Liu, H.; Huang, Y.; Ma, B.; Zhang, W.; Liao, C.; Wu, W.; Shao, Y.; Xu, D.; Su, Z.; Lu, W.,

Tanshinones: First-in-Class Inhibitors of the Biogenesis of the Type 3 Secretion System Needle of Pseudomonas aeruginosa for Antibiotic Therapy. *ACS Central Science* **2019**.
81. Abinaya, M.; Gayathri, M., Inhibition of biofilm formation, quorum sensing activity and molecular docking study of isolated 3, 5, 7-Trihydroxyflavone from Alstonia scholaris leaf against P.aeruginosa. *Bioorganic Chemistry* **2019,** *87*, 291-301.
82. Vadakkan, K.; Hemapriya, J.; Selvaraj, V., Quorum quenching intervened in vivo attenuation and immunological clearance enhancement by Solanum torvum root extract against Pseudomonas aeruginosa instigated pneumonia in Sprague Dawley rats. *Clinical Phytoscience* **2019,** *5* (1), 24.
83. Christensen, L. D.; van Gennip, M.; Jakobsen, T. H.; Alhede, M.; Hougen, H. P.; Høiby, N.; Bjarnsholt, T.; Givskov, M., Synergistic antibacterial efficacy of early combination treatment with tobramycin and quorum-sensing inhibitors against Pseudomonas aeruginosa in an intraperitoneal foreign-body infection mouse model. *Journal of Antimicrobial Chemotherapy* **2012,** *67* (5), 1198-1206.
84. Furiga, A.; Lajoie, B.; El Hage, S.; Baziard, G.; Roques, C., Impairment of Pseudomonas aeruginosa Biofilm Resistance to Antibiotics by Combining the Drugs with a New Quorum-Sensing Inhibitor. *Antimicrob Agents Chemother* **2015,** *60* (3), 1676-1686.
85. Bortolotti, D.; Trapella, C.; Bragonzi, A.; Marchetti, P.; Zanirato, V.; Alogna, A.; Gentili, V.; Cervellati, C.; Valacchi, G.; Sicolo, M.; Turrin, G.; Fantinati, A.; Di Luca, D.; Rizzo, R., Conjugation of LasR Quorum-Sensing Inhibitors with Ciprofloxacin Decreases the Antibiotic Tolerance of P. aeruginosa Clinical Strains. *Journal of Chemistry* **2019,** *2019*, 13.
86. Roudashti, S., Zeighami, H., Mirshahabi, H. et al., Synergistic activity of sub-inhibitory concentrations of curcumin with ceftazidime and ciprofloxacin against Pseudomonas aeruginosa quorum sensing related genes and virulence traits. *World Journal of Microbiology and Biotechnology* **2017,** *33* (50).
87. Bahari, S.; Zeighami, H.; Mirshahabi, H.; Roudashti, S.; Haghi, F., Inhibition of Pseudomonas aeruginosa quorum sensing by subinhibitory concentrations of curcumin with gentamicin and azithromycin. *Journal of Global Antimicrobial Resistance* **2017,** *10*, 21-28.
88. Shanmugasundaram, P.; Saroj Kumar, S.; Ubaid, R.; Mahasampath Gowri, S.; Easwaramoorthy, D.; Hemalatha, S., Novel curcumin analogs act as antagonists to control nosocomial infection causing Pseudomonas aeruginosa. *Biocatalysis and Agricultural Biotechnology* **2019,** *20*, 101238.
89. Chanda, W., Joseph, T. P., Padhiar, A. A., Guo, X., Min, L., Wang, W., Lolokote, S., Ning, A., Cao, J., Huang, M., Zhong, M., Combined effect of linolenic acid and tobramycin on Pseudomonas aeruginosa biofilm formation and quorum sensing. *Experimental and Theraputic Medicine* **2017,** *14* (5).
90. Brackman, G.; Cos, P.; Maes, L.; Nelis, H. J.; Coenye, T., Quorum sensing inhibitors increase the susceptibility of bacterial biofilms to antibiotics in vitro and in vivo. *Antimicrob Agents Chemother* **2011,** *55* (6), 2655-2661.
91. Yin, J.; Xing, H.; Ye, J., Efficacy of berberine in patients with type 2 diabetes mellitus. *Metabolism* **2008,** *57* (5), 712-717.
92. Yu, H. H.; Kim, K. J.; Cha, J. D.; Kim, H. K.; Lee, Y. E.; Choi, N. Y.; You, Y. O., Antimicrobial activity of berberine alone and in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus. *J Med Food* **2005,** *8* (4), 454-61.
93. Li, Y.; Huang, J.; Li, L.; Liu, L., Synergistic Activity of Berberine with Azithromycin against Pseudomonas Aeruginosa Isolated from Patients with Cystic Fibrosis of Lung In Vitro and In Vivo. *Cellular Physiology and Biochemistry* **2017,** *42* (4), 1657-1669.
94. Fong, J.; Mortensen, K. T.; Nørskov, A.; Qvortrup, K.; Yang, L.; Tan, C. H.; Nielsen, T. E.; Givskov, M., Itaconimides as Novel Quorum Sensing Inhibitors of Pseudomonas aeruginosa. *Frontiers in Cellular and Infection Microbiology* **2019,** *8* (443).
95. Baba, S. P.; Bhatnagar, A., ROLE OF THIOLS IN OXIDATIVE STRESS. *Curr Opin Toxicol* **2018,** *7*, 133-139.
96. Thomann, A.; de Mello Martins, A. G. G.; Brengel, C.; Empting, M.; Hartmann, R. W., Application of Dual Inhibition Concept within Looped Autoregulatory Systems toward Antivirulence Agents against Pseudomonas aeruginosa Infections. *ACS Chemical Biology* **2016,** *11* (5), 1279-1286.
97. Maura, D.; Rahme, L. G., Pharmacological Inhibition of the Pseudomonas aeruginosa MvfR Quorum-Sensing System Interferes with Biofilm Formation and Potentiates Antibiotic-Mediated Biofilm Disruption. *Antimicrobial Agents and Chemotherapy* **2017,** *61* (12), e01362-17.
98. Heidari, A.; Noshiranzadeh, N.; Haghi, F.; Bikas, R., Inhibition of quorum sensing related virulence factors of Pseudomonas aeruginosa by pyridoxal lactohydrazone. *Microbial Pathogenesis* **2017,** *112*, 103-110.
99. Rajkumari, J.; Borkotoky, S.; Reddy, D.; Mohanty, S. K.; Kumavath, R.; Murali, A.; Suchiang, K.; Busi, S., Anti-quorum sensing and anti-biofilm activity of 5-hydroxymethylfurfural against Pseudomonas aeruginosa PAO1: Insights from in vitro, in vivo and in silico studies. *Microbiological Research* **2019,** *226*, 19-26.
100. Xu, X.-J.; Zeng, T.; Huang, Z.-X.; Xu, X.-F.; Lin, J.; Chen, W.-M., Synthesis and Biological Evaluation of Cajaninstilbene Acid and Amorfrutins A and B as Inhibitors of the Pseudomonas aeruginosa Quorum Sensing System. *Journal of Natural Products* **2018,** *81* (12), 2621-2629.
101. Al-Youssef, H.; Ahmed, A.; A. Al-Shabib, N.; Laeeq, S.; Khan, R. A.; Mt, R.; Alsalme, A.; Alajmi, M.; Khan, M.; Husain, F., Onion Peel Ethylacetate Fraction and Its Derived Constituent Quercetin 4'-O-β-D Glucopyranoside Attenuates Quorum Sensing Regulated Virulence and Biofilm Formation. *Frontiers in Microbiology* **2017,** *8*, 1675.
102. van Tilburg Bernardes, E.; Charron-Mazenod, L.; Reading, D. J.; Reckseidler-Zenteno, S. L.; Lewenza, S., Exopolysaccharide-Repressing Small Molecules with Antibiofilm and Antivirulence Activity against Pseudomonas aeruginosa. *Antimicrobial Agents and Chemotherapy* **2017,** *61* (5), e01997-16.
103. Jennings, L. K.; Storek, K. M.; Ledvina, H. E.; Coulon, C.; Marmont, L. S.; Sadovskaya, I.; Secor, P. R.; Tseng, B. S.; Scian, M.; Filloux, A.; Wozniak, D. J.; Howell, P. L.; Parsek, M. R., Pel is a cationic exopolysaccharide that cross-links extracellular DNA in the Pseudomonas aeruginosa biofilm matrix. *Proceedings of the National Academy of Sciences* **2015,** *112* (36), 11353-11358.
104. Colvin, K. M.; Gordon, V. D.; Murakami, K.; Borlee, B. R.; Wozniak, D. J.; Wong, G. C. L.; Parsek, M. R., The Pel Polysaccharide Can Serve a Structural and Protective Role in the Biofilm Matrix of Pseudomonas aeruginosa. *PLOS Pathogens* **2011,** *7* (1), e1001264.
105. Irie, Y.; Borlee, B. R.; O'Connor, J. R.; Hill, P. J.; Harwood, C. S.; Wozniak, D. J.; Parsek, M. R., Self-produced exopolysaccharide is a signal that stimulates biofilm formation in Pseudomonas aeruginosa. *Proceedings of the National Academy of Sciences* **2012,** *109* (50), 20632-20636.
106. Yang, L.; Hu, Y.; Liu, Y.; Zhang, J.; Ulstrup, J.; Molin, S., Distinct roles of extracellular polymeric substances in Pseudomonas

aeruginosa biofilm development. *Environmental Microbiology* **2011,** *13* (7), 1705-1717.

107. van Tilburg Bernardes, E.; Charron-Mazenod, L.; Reading, D. J.; Reckseidler-Zenteno, S. L.; Lewenza, S., Exopolysaccharide-Repressing Small Molecules with Antibiofilm and Antivirulence Activity against Pseudomonas aeruginosa. *Antimicrob Agents Chemother* **2017,** *61* (5).

108. Nesterenko, L. N.; Zigangirova, N. A.; Zayakin, E. S.; Luyksaar, S. I.; Kobets, N. V.; Balunets, D. V.; Shabalina, L. A.; Bolshakova, T. N.; Dobrynina, O. Y.; Gintsburg, A. L., A small-molecule compound belonging to a class of 2,4-disubstituted 1,3,4-thiadiazine-5-ones suppresses Salmonella infection in vivo. *The Journal Of Antibiotics* **2016,** *69*, 422.

109. Diepold, A.; Armitage, J. P., Type III secretion systems: the bacterial flagellum and the injectisome. *Philosophical Transactions of the Royal Society B: Biological Sciences* **2015,** *370* (1679), 20150020.

110. Hauser, A. R., Pseudomonas aeruginosa: so many virulence factors, so little time. *Crit Care Med* **2011,** *39* (9), 2193-2194.

111. Anantharajah, A.; Buyck, J. M.; Sundin, C.; Tulkens, P. M.; Mingeot-Leclercq, M.-P.; Van Bambeke, F., Salicylidene Acylhydrazides and Hydroxyquinolines Act as Inhibitors of Type Three Secretion Systems in Pseudomonas aeruginosa by Distinct Mechanisms. *Antimicrobial Agents and Chemotherapy* **2017,** *61* (6), e02566-16.

112. Haiko, J.; Westerlund-Wikström, B., The role of the bacterial flagellum in adhesion and virulence. *Biology* **2013,** *2* (4), 1242-1267.

113. Young, G. M.; Schmiel, D. H.; Miller, V. L., A new pathway for the secretion of virulence factors by bacteria: the flagellar export apparatus functions as a protein-secretion system. *Proceedings of the National Academy of Sciences of the United States of America* **1999,** *96* (11), 6456-6461.

114. Corech, R.; Rao, A.; Laxova, A.; Moss, J.; Rock, M. J.; Li, Z.; Kosorok, M. R.; Splaingard, M. L.; Farrell, P. M.; Barbieri, J. T., Early immune response to the components of the type III system of Pseudomonas aeruginosa in children with cystic fibrosis. *Journal of clinical microbiology* **2005,** *43* (8), 3956-62.

115. Quinaud, M.; Chabert, J.; Faudry, E.; Neumann, E.; Lemaire, D.; Pastor, A.; Elsen, S.; Dessen, A.; Attree, I., The PscE-PscF-PscG Complex Controls Type III Secretion Needle Biogenesis in Pseudomonas aeruginosa. *Journal of Biological Chemistry* **2005,** *280* (43), 36293-36300.

116. Kurahashi, K.; Kajikawa, O.; Sawa, T.; Ohara, M.; Gropper, M. A.; Frank, D. W.; Martin, T. R.; Wiener-Kronish, J. P., Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia. *J Clin Invest* **1999,** *104* (6), 743-50.

117. Hauser, A. R., The type III secretion system of Pseudomonas aeruginosa: infection by injection. *Nature Reviews Microbiology* **2009,** *7*, 654.

118. Vareechon, C.; Zmina, S. E.; Karmakar, M.; Pearlman, E.; Rietsch, A., Pseudomonas aeruginosa Effector ExoS Inhibits ROS Production in Human Neutrophils. *Cell Host & Microbe* **2017,** *21* (5), 611-618.e5.

119. Shafikhani, S. H.; Engel, J., Pseudomonas aeruginosa type III-secreted toxin ExoT inhibits host-cell division by targeting cytokinesis at multiple steps. *Proc Natl Acad Sci U S A* **2006,** *103* (42), 15605-15610.

120. Garai, P.; Berry, L.; Moussouni, M.; Bleves, S.; Blanc-Potard, A.-B., Killing from the inside: Intracellular role of T3SS in the fate of Pseudomonas aeruginosa within macrophages revealed by mgtC and oprF mutants. *PLOS Pathogens* **2019,** *15* (6), e1007812.

121. Yahr, T. L.; Wolfgang, M. C., Transcriptional regulation of the Pseudomonas aeruginosa type III secretion system. *Molecular Microbiology* **2006,** *62* (3), 631-640.

122. Maura, D.; Ballok, A. E.; Rahme, L. G., Considerations and caveats in anti-virulence drug development. *Current Opinion in Microbiology* **2016,** *33*, 41-46.

123. Muschiol, S.; Normark, S.; Henriques-Normark, B.; Subtil, A., Small molecule inhibitors of the Yersinia type III secretion system impair the development of Chlamydia after entry into host cells. *BMC Microbiology* **2009,** *9* (1), 75.

124. Veenendaal, A. K. J.; Sundin, C.; Blocker, A. J., Small-Molecule Type III Secretion System Inhibitors Block Assembly of the Shigella Type III Secreton. *Journal of Bacteriology* **2009,** *191* (2), 563-570.

125. Enquist, P.-A.; Gylfe, Å.; Hägglund, U.; Lindström, P.; Norberg-Scherman, H.; Sundin, C.; Elofsson, M., Derivatives of 8-hydroxyquinoline—antibacterial agents that target intra- and extracellular Gram-negative pathogens. *Bioorganic & Medicinal Chemistry Letters* **2012,** *22* (10), 3550-3553.

126. Sheremet, A. B.; Zigangirova, N. A.; Zayakin, E. S.; Luyksaar, S. I.; Kapotina, L. N.; Nesterenko, L. N.; Kobets, N. V.; Gintsburg, A. L., Small Molecule Inhibitor of Type Three Secretion System Belonging to a Class 2,4-disubstituted-4H-[1,3,4]-thiadiazine-5-ones Improves Survival and Decreases Bacterial Loads in an Airway Pseudomonas aeruginosa Infection in Mice. *Biomed Res Int* **2018,** *2018*, 5810767-5810767.

127. Anantharajah, A.; Mingeot-Leclercq, M.-P.; Van Bambeke, F., Targeting the Type Three Secretion System in Pseudomonas aeruginosa. *Trends in Pharmacological Sciences* **2016,** *37* (9), 734-749.

128. Duncan, M. C.; Linington, R. G.; Auerbuch, V., Chemical inhibitors of the type three secretion system: disarming bacterial pathogens. *Antimicrob Agents Chemother* **2012,** *56* (11), 5433-5441.

129. Sheremet, A. B.; Zigangirova, N. A.; Zayakin, E. S.; Luyksaar, S. I.; Kapotina, L. N.; Nesterenko, L. N.; Kobets, N. V.; Gintsburg, A. L., Small Molecule Inhibitor of Type Three Secretion System Belonging to a Class 2,4-disubstituted-4H-[1,3,4]-thiadiazine-5-ones Improves Survival and Decreases Bacterial Loads in an Airway Pseudomonas aeruginosa Infection in Mice. *BioMed Research International* **2018,** *2018*, 13.

130. Nepali, K.; Lee, H.-Y.; Liou, J.-P., Nitro-Group-Containing Drugs. *Journal of Medicinal Chemistry* **2019,** *62* (6), 2851-2893.

131. Miao, E. A.; Ernst, R. K.; Dors, M.; Mao, D. P.; Aderem, A., Pseudomonas aeruginosa activates caspase 1 through Ipaf. *Proceedings of the National Academy of Sciences* **2008,** *105* (7), 2562-2567.

132. Palmer, G. C.; Whiteley, M., Metabolism and Pathogenicity of Pseudomonas aeruginosa Infections in the Lungs of Individuals with Cystic Fibrosis. *Microbiol Spectr* **2015,** *3* (4).



Virulence Attenuating Combination Therapy may be a promising approach to treating chronic *P. aeruginosa* infections in patients with cystic fibrosis.